Even as regulators are cracking down on pharmacy benefit managers, some payers have been leaning into their own businesses in 2025. Here are six payer moves indicating growing PBM interest: 1.
Fall enrollment is on. Some plans are raising premiums for Part D, which covers prescriptions, by $50 or more per month, while others are lowering them. By Mark Miller Holly Kluck found a great price ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. The Food and Drug Administration on Thursday delivered a split decision ...
CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare ...
Hosted on MSN
GSK Executives Acquire Shares Under Reward Plan
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. GlaxoSmithKline ( (GB:GSK)) just unveiled ...
Commitment to supporting unique member needs — those living with chronic conditions and individuals dually eligible for both Medicare and Medicaid Leveraging the strength of the CVS Health family of ...
Shares of GSK rallied on Monday after the U.K. pharmaceutical giant turned to an insider to become its next CEO. Luke Miels, chief commercial officer, will take the reigns on Jan. 1 from Emma Walmsley ...
GSK GSK0.19%increase; green up pointing triangle said Chief Executive Emma Walmsley would step down and be succeeded by commercial chief Luke Miels, as the drugmaker works to replenish its product ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — GSK on Monday said that Luke Miels, the company’s chief ...
Following the Trump administration's plans to explore whether a widely available generic medication called leucovorin could cure autism, GSK (NYSE:GSK), which once manufactured and marketed the ...
GSK plc announced Wednesday that it will invest roughly $1.2B to build a new facility for pharmaceutical manufacturing and research and development in Upper Merion, Pennsylvania, as well as to upgrade ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results